Navigation Links
Axela Inc. Retains Investment Bank to Evaluate Strategic Opportunities
Date:2/1/2013

TORONTO, Feb. 1, 2013 /PRNewswire/ -- Axela Inc. announced it has appointed AmeriTech Advisors healthcare investment banking team to respond to recent strategic interest from life science industry companies. This involves licensing or sale of rights to certain of the company's recently developed multiplex tests and proprietary platform technologies.

Over the last 2 years Axela has successfully transformed itself from being an engineering based, life-science tools company, into a strategically focused solutions provider, poised to exploit large market opportunities in Cancer, Immunology, Specialty Diagnostic and Life Science markets.  Axela has focused its MDX applications on rapidly growing markets which demand the combination of high numbers of gene and/or protein markers, rapid results and competitive pricing.

Axela's Flow-thru Array® platform addresses the gap that exists between multiplexed nucleic acid PCR and high density DNA/RNA arrays. The Ziplex® platform is more cost effective and unlike existing approaches, can be readily integrated into established laboratory workflows while  measuring 125-150 genes.  Recently, capabilities have been expanded to include fully automated multiplex protein analysis, offering significant advantages over bead or plate based platforms.  Ziplex, which is patented with extensive freedom to operate, can simultaneously measure more than 50 proteins rapidly while consuming only a few microliters of sample.  Performance has been demonstrated in infectious diseases, traumatic brain injury, and allergy testing applications.

Axela has also significantly advanced the company's second generation diffractive optics platform in collaboration with SONY DADC as part of a development program called ClearDx. The result is a cost efficient and very flexible protein multiplexing platform designed to move the delivery of Personalized Medicine closer to the patient. The platform is supported by a large patent estate and is uniquely well positioned to deliver highly informative assays in multiplex format (32+) at the point of use for human and veterinary diagnostics, research or bioproduction monitoring.

Strategic alternatives the Company may pursue could include a merger, partnering or other collaboration agreements, an equity or debt financing, sale of the Company or other strategic transactions.  The Company does not intend to disclose developments with respect to this process until the evaluation of strategic alternatives has been completed and the board of directors has approved a specific transaction.

About AmeriTech Advisors
AmeriTech is an investment bank dedicated to providing capital raising and strategic advisory services to emerging growth companies in the technology and medtech sectors with market capitalizations of between $25 million and $500 million. Their bankers have 20 years' experience at major global investment banks and as senior managers at public companies with experience executing successful transactions. Their goal is to build mutually beneficial relationships between our emerging growth company clients, technology and medtech/pharma partners, and their network of investors.

Contact:
Dan D'Agostino
Managing Director
AmeriTech Advisors
708 Third Avenue, 5th fl.
New York, NY 10017
T: 212-209-3885
C: 917-596-9870
F: 212-209-7101
ddagostino@ameritechadvisors.com

Member FINRA/SIPC.

 


'/>"/>
SOURCE AmeriTech Advisors
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
2. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
3. Life Technologies to Present at Upcoming Investment Conferences in February
4. New investment aims to establish the UK as a global graphene research hub
5. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
6. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
7. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
8. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
9. Foundation Venture Capital Group Makes Eighth Start-Up Investment
10. Israeli Ministry of Finance Hosts Israel Investment, Innovation and Trade Forum in New York
11. David Lichtenstein: Biotechnology is Rich Area for Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox ... response to client demand KbioBox developed a sophisticated “3 click” gene dditing off ... accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered by the ...
(Date:12/8/2016)... ... ... This CAST literature review and report looks at problems caused by the current ... in countries that are major global commodity exporters and importers, which show that asynchrony ... level presence (LLP) puts large volumes of trade worth billions of dollars at risk. ...
(Date:12/8/2016)... TAMPA, Fla. , Dec. 8, 2016 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that its shares of common stock were approved ... stock will begin trading on the OTCQX, effective ... To qualify for the OTCQX market, companies must ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):